莫西沙星与头孢哌酮/舒巴坦联用对金黄色葡萄球菌等多重耐药菌的体外抗菌效果研究  

In Vitro Antibacterial Activitey of Moxifloxacin Combined with Cefoperazone/Sulbactam Against Multidrug Resistant Bacteria

作　　者：吴丽萌[1] 赖东梅[1] 陈光龙[1] 

机构地区：[1]深圳市宝安区人民医院药剂科,深圳市518101

出　　处：《中国药房》2009年第29期2277-2279,共3页China Pharmacy

摘　　要：目的:探讨莫西沙星与头孢哌酮/舒巴坦联用对临床常见耐药菌的抗菌效果,为临床合理应用抗菌药物提供参考。方法:采用Vitek-32型全自动细菌鉴定仪,测定2种抗生素单用和联用分别对50株金黄色葡萄球菌、肺炎克雷伯菌和铜绿假单胞菌及20株大肠埃希菌、阴沟肠杆菌的最低抑菌浓度(MIC),并计算联合药敏指数。结果:2药联用对临床分离的190株常见耐药致病菌的MIC均明显降低、抗菌作用增强,体外抗菌作用以协同作用和相加作用为主。结论:本研究对指导医院常见耐药菌感染的治疗具有参考价值。OBJECTIVE： To evaluate the antibiotic activity of Moxifloxacin （MFX） combined with Cefoperazone / Sulbactam （CPZ/ SBT） against clinical common resistant bacteria for clinical reference of rational use of antibacterials. METHODS： The MIC of two antibiotics used alone or in combination on staphylococcus aureus, Ktebsiella pneumoniae, Pseudomonas aeruginosas（50 strains, respectively） and Escherichia coli, enterobacter cloacae（20 strains, respectively） were detected respectively by Vitek- 32 Model （Full Automated bacterium Detection Device） and the fractional inhibitory concentration（FIC） index was calculated. RESULTS： The combination of two antibiotics significantly reduced MIC on 190 common resistant pathogenic strains and enhanced antibiotic action. Their antibacterial action in vitro was characterized by synergism and additive action. CONCLUSION： The study can present reference for hospital treatment of infection induced by common drugresistant bacteria.

关 键 词：莫西沙星 头孢哌酮/舒巴坦 联合用药 最低抑菌浓度 联合药敏指数 

分 类 号：R969.3[医药卫生—药理学]